Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta

Anna Paola Batocchi; Mario Rotondi; Marcella Caggiula; Giovanni Frisullo; Francesca Odoardi; Viviana Nociti; Carlo Carella; Pietro Attilio Tonali; Massimiliano Mirabella

doi:10.1016/S0165-5728(03)00154-1

Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta

Anna Paola Batocchi, Mario Rotondi, Marcella Caggiula, Giovanni Frisullo, Francesca Odoardi, Viviana Nociti, Carlo Carella, Pietro Attilio Tonali, Massimiliano Mirabella

Research output: Contribution to journal › Article › peer-review

Abstract

The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.

Original language	English
Pages (from-to)	150-154
Number of pages	5
Journal	Journal of Neuroimmunology
Volume	139
Issue number	1-2
DOIs	https://doi.org/10.1016/S0165-5728(03)00154-1
Publication status	Published - Jun 2003

Keywords

Cytokines
Interferon beta
Leptin
Multiple sclerosis

ASJC Scopus subject areas

Immunology
Clinical Neurology
Immunology and Allergy
Neurology

Access to Document

10.1016/S0165-5728(03)00154-1

Cite this

Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. / Batocchi, Anna Paola; Rotondi, Mario; Caggiula, Marcella; Frisullo, Giovanni; Odoardi, Francesca; Nociti, Viviana; Carella, Carlo; Tonali, Pietro Attilio; Mirabella, Massimiliano.

In: Journal of Neuroimmunology, Vol. 139, No. 1-2, 06.2003, p. 150-154.

Research output: Contribution to journal › Article › peer-review

@article{c803f6cbaaed499490d4b25c313107e6,

title = "Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta",

abstract = "The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.",

keywords = "Cytokines, Interferon beta, Leptin, Multiple sclerosis",

author = "Batocchi, {Anna Paola} and Mario Rotondi and Marcella Caggiula and Giovanni Frisullo and Francesca Odoardi and Viviana Nociti and Carlo Carella and Tonali, {Pietro Attilio} and Massimiliano Mirabella",

year = "2003",

month = jun,

doi = "10.1016/S0165-5728(03)00154-1",

language = "English",

volume = "139",

pages = "150--154",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier Science B.V.",

number = "1-2",

}

TY - JOUR

T1 - Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta

AU - Batocchi, Anna Paola

AU - Rotondi, Mario

AU - Caggiula, Marcella

AU - Frisullo, Giovanni

AU - Odoardi, Francesca

AU - Nociti, Viviana

AU - Carella, Carlo

AU - Tonali, Pietro Attilio

AU - Mirabella, Massimiliano

PY - 2003/6

Y1 - 2003/6

N2 - The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.

AB - The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.

KW - Cytokines

KW - Interferon beta

KW - Leptin

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0038797814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038797814&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(03)00154-1

DO - 10.1016/S0165-5728(03)00154-1

M3 - Article

C2 - 12799033

AN - SCOPUS:0038797814

VL - 139

SP - 150

EP - 154

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -

Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this